This study used data that we collected previously for our PCOS GWAS (Hayes and Urbanek et al. Nat Commun 6:7502, 2015) \[[@pmed.1003132.ref019]\]. Stage 1 genotype data have been deposited in the database of Genotypes and Phenotypes (dbGaP) under the accession code phs000368.v1.p1 (<https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000368.v1.p1>). The following variables are provided along with the genotype data: SUBJID (de-identified), Case_Control (disease status), Sex, Age, Height, Weight, BMI, Race, Ethnicity. Subtype classifications for these subjects are provided in [S5 Table](#pmed.1003132.s006){ref-type="supplementary-material"}. This study used additional array and whole-genome sequencing data from human subjects. The majority of study subjects were enrolled prior to the implementation of the NIH Genomic Data Sharing Policy in January 25, 2015. Consequently, none of the consent forms directly addressed the broad sharing of participants' data nor the risks associated with broad data sharing of these data. Further, consent forms limited the use of the DNA samples from PCOS cases to genetic analyses of this disorder. Therefore, individual-level data cannot be shared through NIH-designated repositories without approval of the Institutional Review Boards (IRBs) where the cohort was originally studied. Access to aggregate data must be limited to genetic analyses of PCOS and require approval of all relevant IRBs. Investigators may contact individual site PIs from Hayes & Urbanek et al. \[[@pmed.1003132.ref019]\] or Kelly Brewer at <kelly.brewer@mssm.edu> if they are interested in collaborating on a project that requires use of quantitative trait data. The R code used to perform the clustering and subsequent family cohort classification have been uploaded to the following public GitHub repository: github.com/mdapas/PCOS_phenotype_clustering.

Introduction {#sec007}
============

Understanding the genetic architecture of complex diseases is a central challenge in human genetics \[[@pmed.1003132.ref001]--[@pmed.1003132.ref003]\]. Often defined according to arbitrary diagnostic criteria, complex diseases can represent the phenotypic convergence of numerous genetic etiologies under the same clinical diagnosis \[[@pmed.1003132.ref004]--[@pmed.1003132.ref008]\]. Recent studies in type 2 diabetes (T2D) support the concept that there are disease subtypes with distinct genetic architecture \[[@pmed.1003132.ref007],[@pmed.1003132.ref008]\]. Identifying and addressing genetic heterogeneity in complex diseases could increase power to detect causal variants and improve treatment efficacy \[[@pmed.1003132.ref009]\].

Polycystic ovary syndrome (PCOS) is a highly heritable, complex genetic disorder affecting up to 15% of reproductive-age women worldwide, depending on the diagnostic criteria applied \[[@pmed.1003132.ref010]\]. It is characterized by a variable constellation of reproductive and metabolic abnormalities \[[@pmed.1003132.ref011]--[@pmed.1003132.ref013]\]. It is the leading cause of anovulatory infertility and a major risk factor for T2D in young women \[[@pmed.1003132.ref014]\]. Despite these substantial morbidities, the etiology (or etiologies) of PCOS remains unknown \[[@pmed.1003132.ref015]\]. Accordingly, the commonly used diagnostic criteria for PCOS, the National Institutes of Health (NIH) criteria \[[@pmed.1003132.ref016]\] and the Rotterdam criteria \[[@pmed.1003132.ref017],[@pmed.1003132.ref018]\], are based on expert opinion rather than mechanistic insights and are designed to account for the diverse phenotypic presentations of PCOS. The NIH criteria require the presence of hyperandrogenism (HA) and chronic oligo/anovulation or ovulatory dysfunction (OD) \[[@pmed.1003132.ref016]\]. The Rotterdam criteria include polycystic ovarian morphology (PCOM) and require the presence of at least 2 of these 3 key reproductive traits, resulting in 3 different affected phenotypes: HA and OD with or without PCOM, also known as NIH PCOS, as well as 2 additional non-NIH Rotterdam phenotypes, HA and PCOM and OD and PCOM.

Genome-wide association studies (GWAS) have considerably advanced our understanding of the pathophysiology of PCOS. These studies have implicated gonadotropin secretion \[[@pmed.1003132.ref019]\] and action \[[@pmed.1003132.ref020],[@pmed.1003132.ref021]\], androgen biosynthesis \[[@pmed.1003132.ref020]--[@pmed.1003132.ref022]\], metabolic regulation \[[@pmed.1003132.ref022],[@pmed.1003132.ref023]\], and ovarian aging \[[@pmed.1003132.ref023]\] in PCOS pathogenesis. A recent meta-analysis \[[@pmed.1003132.ref022]\] of GWAS was the first study to investigate the genetic architecture of the diagnostic criteria. Only one of 14 PCOS susceptibility loci identified was significantly more strongly associated with the NIH phenotype compared to non-NIH Rotterdam phenotypes or to self-reported PCOS. These findings suggested that the genetic architecture of the phenotypes defined by the different PCOS diagnostic criteria were generally similar. Therefore, the current diagnostic criteria do not appear to identify genetically distinct disease subtypes.

It is possible to identify physiologically relevant complex disease subtypes through cluster analysis of phenotypic traits \[[@pmed.1003132.ref008],[@pmed.1003132.ref024],[@pmed.1003132.ref025]\]. Indeed, there have been previous efforts to subtype PCOS using unsupervised cluster analysis of its hormonal and anthropometric traits \[[@pmed.1003132.ref026]--[@pmed.1003132.ref029]\]. However, there has been no validation that the resulting PCOS subtypes were biologically meaningful by testing their association with genetic variants, with other independent biomarkers, or with outcomes such as therapeutic responses. In this study, we sought to 1) identify phenotypic subtypes of PCOS using an unsupervised clustering approach on reproductive and metabolic quantitative traits from a large cohort of women with PCOS, 2) validate those subtypes in an independent cohort, and 3) test whether the subtypes thus identified were associated with distinct common genetic variants. As an additional validation, we investigated the association of the subtypes with rare genetic variants we recently identified in a family-based PCOS cohort \[[@pmed.1003132.ref030]\].

Methods {#sec008}
=======

Subjects {#sec009}
--------

This study used biochemical and genotype data from our previously published PCOS GWAS, Hayes and Urbanek and colleagues \[[@pmed.1003132.ref019]\], in which a discovery sample (Stage 1) of 984 unrelated PCOS cases and 2,964 population controls was studied, followed by a replication sample (Stage 2) of 1,799 PCOS cases and 1,231 phenotyped reproductively normal control women. All cases were of European ancestry. The present study began as an exploratory analysis to test the hypothesis that subtypes existed within the PCOS GWAS cohorts. Further analyses were performed once subtypes were identified. This study is reported according to the Strengthening the Reporting of Genetic Association Studies (STREGA) guideline ([S1 Checklist](#pmed.1003132.s001){ref-type="supplementary-material"}). The study was approved by the Institutional Review Board of Northwestern University Feinberg School of Medicine, and each subject provided written informed consent prior to the study \[[@pmed.1003132.ref019]\].

All PCOS cases were aged 13--45 years and were diagnosed according to the NIH criteria \[[@pmed.1003132.ref010]\] of hyperandrogenism and chronic anovulation (8 or fewer menses per year), excluding specific disorders of the adrenal glands, ovaries, or pituitary gland \[[@pmed.1003132.ref031]\]. Cases fulfilling the NIH criteria also meet the Rotterdam criteria for PCOS \[[@pmed.1003132.ref010]\]. The GWAS cohorts included in the cluster analysis, the PCOS Family Study and Pregnancy in PCOS II (PPCOSII) study \[[@pmed.1003132.ref019]\] ([S1 Table](#pmed.1003132.s002){ref-type="supplementary-material"}), had complete data for the following traits: body mass index (BMI), testosterone (T), sex hormone binding globulin (SHBG), dehydroepiandrosterone sulfate (DHEAS), luteinizing hormone (LH), follicle-stimulating hormone (FSH), fasting insulin (Ins0), and fasting glucose (Glu0). Complete data for these quantitative traits were not available in the other GWAS cohorts because of differences in phenotyping protocols \[[@pmed.1003132.ref019]\] ([S1 Table](#pmed.1003132.s002){ref-type="supplementary-material"}). Two additional NIH PCOS cohorts with complete quantitative trait data were included in the present study. An ungenotyped cohort of 263 cases was used for clustering replication. A family-based whole-genome sequencing cohort of 73 PCOS cases was investigated to assess subtype clustering in families and for rare variant analysis \[[@pmed.1003132.ref030]\].

Contraceptive steroids had been stopped at least 3 months prior to screening for the PCOS Family Study, ungenotyped, and whole-genome sequencing PCOS cohorts. Elevated T, non-SHBG bound T, and/or DHEAS levels were documented in all PCOS cases prior to enrollment in these cohorts. PPCOSII was a randomized clinical trial of letrozole versus clomiphene citrate for infertility in PCOS \[[@pmed.1003132.ref032]\]. The PCOS cases in this study had contraceptive steroids discontinued at least 2 months prior to their baseline phenotyping visit. Since the PCOS women in this trial were seeking fertility, the majority were not on recent contraceptive steroid therapy. Therefore, it is unlikely that recent contraceptive steroid use altered T or SHBG levels in the PCOS cases included in the cluster analysis.

All subjects included in the cluster analysis were from US-based study sites. The GWAS Stage 2 replication included 2 cohorts from Europe in addition to US-based cohorts \[[@pmed.1003132.ref019]\]. Neither European cohort was included in the cluster analysis because of incomplete quantitative trait data. We compared age and BMI in the cohorts included in the cluster analysis of cases with complete quantitative trait data versus cases from the same cohort not included because of missing data. There were no significant differences in these parameters, suggesting that the included cases were similar to those excluded because of missing data ([S2 Table](#pmed.1003132.s003){ref-type="supplementary-material"}).

Population-based control DNA samples for the GWAS Stage 1 sample were obtained from the NUgene biobank \[[@pmed.1003132.ref033]\] from women of European ancestry, aged 18--97 years. Control women in the Stage 2 sample were phenotyped reproductively normal women of European ancestry, aged 15--45 years, with regular menses and normal T levels, and who were not receiving contraceptive steroids for at least 3 months prior to study \[[@pmed.1003132.ref019]\]. T, DHEAS, SHBG, LH, FSH, Glu0, and Ins0 levels were measured as previously reported \[[@pmed.1003132.ref019]\].

Clustering {#sec010}
----------

Clustering was performed in PCOS cases on 8 adjusted quantitative traits: BMI, T, DHEAS, Ins0, Glu0, SHBG, LH, and FSH. There were 893 combined cases from the GWAS samples with complete quantitative trait data available for clustering. Quantitative trait values were first log~e~-normalized and adjusted for age and assay method, which varied according to the different study sites where samples were collected \[[@pmed.1003132.ref019]\], using a linear regression. An inverse normal transformation was then applied for each trait to ensure equal scaling. The normalized trait residuals were clustered using unsupervised, agglomerative, hierarchical clustering according to a generalization of Ward's minimum variance method \[[@pmed.1003132.ref034],[@pmed.1003132.ref035]\] on Manhattan distances between trait values. Differences in adjusted, normalized trait values between subtypes were assessed using Kruskal--Wallis and unpaired Wilcoxon rank--sum tests corrected for multiple testing (Bonferroni). Cluster stability was assessed by computing the mean Jaccard coefficient from a repeated nonparametric bootstrap resampling (n = 1,000) of the dissimilarity matrix \[[@pmed.1003132.ref036]\]. Jaccard coefficients below 0.5 indicate that a cluster does not capture any discernable pattern within the data, while a mean coefficient above 0.6 indicates that the cluster reflects a real pattern within the data \[[@pmed.1003132.ref036]\]. Cluster reproducibility was further assessed by repeating the clustering procedure in an independent cohort of 263 PCOS cases.

Association testing {#sec011}
-------------------

Stage 1 samples were genotyped using the Illumina OmniExpress (HumanOmniExpress-12v1_C; San Diego, CA, USA) single nucleotide polymorphism (SNP) array. Stage 2 samples were genotyped using the Metabochip \[[@pmed.1003132.ref037]\] with added custom variant content based on ancillary studies and the discovery results \[[@pmed.1003132.ref019]\]. The Stage 2 association replication in this study was therefore limited; many of the loci from Stage 1 were therefore not characterized in Stage 2. Low-quality genotypic data were removed as described previously \[[@pmed.1003132.ref019]\]. SNPs were filtered according to minor allele frequency (MAF ≥ 0.01), Hardy--Weinberg equilibrium (*P* ≥ 1 × 10^−6^), call rate (≥0.99), minor allele count (MAC \> 5), mendelian concordance, and duplicate sample concordance. Only autosomal SNPs were considered. Ancestry was evaluated using a principal component analysis (PCA) \[[@pmed.1003132.ref038]\] on 76,602 linkage disequilibrium (LD)-pruned SNPs \[[@pmed.1003132.ref019]\]. Samples with values \>3 standard deviations from the median for either of the first 2 principal components (PCs) were excluded (34 in discovery; 37 in replication). Genotype data were phased using ShapeIT (v2.r790) \[[@pmed.1003132.ref039]\] and then imputed to the 1000 Genomes reference panel (Phase3 v5) \[[@pmed.1003132.ref040]\] using Minimac3 via the Michigan Imputation Server \[[@pmed.1003132.ref041]\]. Imputed SNPs with an allelic r^2^ below 0.8 were removed from analysis \[[@pmed.1003132.ref042]\].

Association testing was performed separately for Stage 1 and Stage 2 samples. Of the 893 combined cases from both stages included in the clustering analysis, 555 were from the Stage 1 sample, and 338 were from the Stage 2 sample. In Stage 1, 2,964 normal controls were used, and 1,134 were used in Stage 2. Logistic regressions were performed using SNPTEST \[[@pmed.1003132.ref043]\] for case--control status under an additive genetic model, adjusting for BMI and first 3 PCs of ancestry. P-values are reported as P~1~ and P~2~ for Stage 1 and Stage 2, respectively. Cases were limited to specific subtypes selected from clustering results. The betas and standard errors were combined across Stage 1 and Stage 2 samples for each subtype under a fixed meta-analysis model weighting each strata by sample size \[[@pmed.1003132.ref044]\]. Association test outputs were aligned to the same reference alleles and weighted z-scores were computed for each SNP. The square roots of each sample size were used as the proportional weights. Meta-analysis P-values (P~meta~) were adjusted for genomic inflation. Associations with P-values \< 1.67 × 10^−8^ were considered statistically significant, based on the standard *P* \< 5 × 10^−8^ used in conventional GWAS adjusted for the 3 independent association tests performed.

Chromatin interactions {#sec012}
----------------------

Neighboring chromatin interactions were investigated in intergenic loci using high-throughput chromatin conformation capture (Hi-C) data from the 3DIV database \[[@pmed.1003132.ref045]\]. Topologically associating domains (TADs) were identified using TopDom \[[@pmed.1003132.ref046]\] with a window size of 20.

Identifying subtypes in PCOS families {#sec013}
-------------------------------------

Quantitative trait data from the affected women (n = 73) in the family-sequencing cohort \[[@pmed.1003132.ref030]\] were adjusted and normalized as described above. Subtype classifiers were modeled on the adjusted trait values and cluster assignments from the genotyped clustering cohort. Several classification methods were compared using 10-fold cross-validation, including support vector machine (SVM), random forest (RF), Gaussian mixed model (GMM), and quadratic discriminant analysis (QDA) \[[@pmed.1003132.ref047]\]. The classifier with the lowest error rate was then applied to the affected women in the family-sequencing cohort to identify subtypes of PCOS in the family data. Some of the probands from the family-based cohort were included in our previous GWAS \[[@pmed.1003132.ref019]\]. Therefore, there was some sample overlap between the training and test data: of the 893 genotyped women used to identify the original subtype clusters, 47 were also probands in the family-based cohort. Differences between subtypes in the proportion of women with *DENND1A* rare variants were tested using the chi-square test of independence.

Results {#sec014}
=======

PCOS subtypes {#sec015}
-------------

Clustering was first performed in a cohort of 893 genotyped PCOS cases ([Table 1](#pmed.1003132.t001){ref-type="table"}, [S3 Table](#pmed.1003132.s004){ref-type="supplementary-material"}). The clustering revealed 2 distinct phenotypic subtypes: 1) a group (23%, 207/893) characterized by higher LH and SHBG levels with relatively low BMI and Ins0 levels, which we designated "reproductive," and 2) a group (37%, 329/893) characterized by higher BMI and Glu0 and Ins0 levels with relatively low SHBG and LH levels, which we designated "metabolic" ([Fig 1](#pmed.1003132.g001){ref-type="fig"}). The key traits distinguishing the reproductive and metabolic subtypes were BMI, insulin, SHBG, glucose, LH, and FSH, in order of importance according to relative unpaired Wilcoxon rank--sum test statistics ([Fig 2](#pmed.1003132.g002){ref-type="fig"}). The remaining cases (40%, 357/893) demonstrated no distinguishable pattern regarding their relative phenotypic trait distributions and were designated "indeterminate" ([S4 Table](#pmed.1003132.s005){ref-type="supplementary-material"}, [S5 Table](#pmed.1003132.s006){ref-type="supplementary-material"}). The reproductive and metabolic subtypes clustered along opposite ends of the SHBG versus Ins0/BMI axis, which was highly correlated with the first PC of the adjusted quantitative traits ([Fig 3](#pmed.1003132.g003){ref-type="fig"}). The reproductive subtype was the most stable cluster, with a mean bootstrapped Jaccard coefficient (${\overline{\gamma}}_{C}$) of 0.61, followed by the metabolic subtype with ${\overline{\gamma}}_{C}$ = 0.55. The indeterminate group did not appear to capture any discernable pattern within the data (${\overline{\gamma}}_{C}$ = 0.41) and was both overlapping and intermediate between the reproductive and metabolic subtypes on the SHBG versus Ins0/BMI axis.

![Hierarchical clustering of genotyped PCOS clustering cohort.\
Hierarchical clustering of 893 genotyped PCOS cases according to adjusted quantitative traits revealed 2 distinct phenotypic subtypes, a "reproductive" cluster, and a "metabolic" cluster; the remaining cases were designated as "indeterminate." The reproductive, metabolic, and indeterminate clusters are shown in the color bar as dark blue, dark red, and gray, respectively. Heatmap colors correspond to trait z-scores, as shown in the frequency histogram in which red indicates high values and blue indicates low values for each trait. The row-based dendrogram represents relative distances between trait distributions and was calculated using the same approach as the subject-based clustering. BMI, body mass index; DHEAS, dehydroepiandrosterone sulfate; FSH, follicle-stimulating hormone; Glu0, fasting glucose; Ins0, fasting insulin; LH, luteinizing hormone; PCOS, polycystic ovary syndrome; SHBG, sex hormone binding globulin; T, testosterone.](pmed.1003132.g001){#pmed.1003132.g001}

![Phenotypic trait distributions in reproductive and metabolic subtypes.\
Median and IQRs are shown for normalized, adjusted quantitative trait distributions of genotyped PCOS cases with reproductive or metabolic subtype. The figure illustrates the traits for which the subtypes differ significantly with an asterisk (\*Bonferroni adjusted Wilcoxon, P~adj~ \< 0.05): Ins0, BMI, Glu0, FSH, LH, and SHBG. BMI, body mass index; DHEAS, dehydroepiandrosterone sulfate; FSH, follicle-stimulating hormone; Glu0, fasting glucose; Ins0, fasting insulin; IQR, interquartile range; LH, luteinizing hormone; PCOS, polycystic ovary syndrome; SHBG, sex hormone binding globulin; T, testosterone.](pmed.1003132.g002){#pmed.1003132.g002}

![PCA plot of quantitative traits for genotyped PCOS clustering cohort.\
Genotyped PCOS cases are plotted on the first 2 PCs of the adjusted quantitative trait data and colored according to their identified subtype. Subtype clusters are shown as 95% concentration ellipses, assuming bivariate normal distributions. The relative magnitude and direction of trait correlations with the PCs are shown with black arrows. BMI, body mass index; DHEAS, dehydroepiandrosterone sulfate; FSH, follicle-stimulating hormone; Glu0, fasting glucose; Ins0, fasting insulin; LH, luteinizing hormone; PC, principal component; PCA, principal component analysis; PCOS, polycystic ovary syndrome; SHBG, sex hormone binding globulin; T, testosterone.](pmed.1003132.g003){#pmed.1003132.g003}

10.1371/journal.pmed.1003132.t001

###### Quantitative traits in cluster analysis PCOS cohorts by assay method.

![](pmed.1003132.t001){#pmed.1003132.t001g}

                      Genotyped   Ungenotyped            Family Sequencing                               
  ------------------- ----------- ---------------------- ------------------- ---------------------- ---- ----------------------
  **Age** (y)         893         28 (25--32)            263                 28 (24--33)            73   28 (25--33)
  **BMI** (kg/m^2^)   893         35.4 (28.2--41.5)      263                 35.7 (28.4--42.3)      73   34.3 (27.8--42.3)
  **T** (ng/dL)                                                                                          
  Method 1            620         72 (60--91)            180                 72 (61--95)            73   73 (64--89)
  Method 2            273         52 (38--69)            83                  65 (50--80)            --   --
  **SHBG** (nmol/L)                                                                                      
  Method 1            554         54 (34--81)            176                 55 (34--82)            72   57 (38--96)
  Method 2            40          34 (22--49)            4                   32 (18--54)            1    37 (37--37)
  Method 3            26          28 (18--41)            --                  --                     --   --
  Method 4            273         30 (21--43)            83                  29 (22--48)            --   --
  **DHEAS** (ng/mL)                                                                                      
  Method 1            620         2,114 (1,513--2,886)   180                 2,190 (1,644--3,004)   73   2,095 (1,509--2,774)
  Method 2            273         1,570 (1,024--2,250)   83                  1,955 (1,040--2,685)   --   --
  **Glu0** (mg/dL)                                                                                       
  Method 1            192         90 (84--96)            84                  92 (88--100)           8    91(87--95)
  Method 2            351         88 (83--95)            136                 89 (84--95)            48   91 (85--96)
  Method 3            238         85 (77--91)            23                  83 (72--89)            --   --
  Method 4            112         87 (81.5--93)          20                  79 (77--88)            17   82 (73--88)
  **Ins0** (μU/mL)                                                                                       
  Method 1            5           19 (15--19)            8                   21 (11--57)            --   --
  Method 2            614         22 (15--34)            173                 23 (16--37)            73   21 (15--30)
  Method 3            238         13 (4--21)             23                  13 (7--22)             --   --
  Method 4            36          22 (15.5--30.5)        59                  21 (15--35)            --   --
  **LH** (mIU/mL)                                                                                        
  Method 1            515         12 (8--18)             173                 12 (7--19)             70   12 (6--18)
  Method 2            73          13 (9--17)             7                   11 (5--15)             3    15 (12--23)
  Method 3            32          9 (6--15)              --                  --                     --   --
  Method 4            273         10 (7--14)             83                  10 (7--14)             --   --
  **FSH** (mIU/mL)                                                                                       
  Method 1            515         9 (7--11)              173                 10 (8--11)             70   9 (8--11)
  Method 2            73          3 (3--4)               7                   4 (2--5)               3    3 (3--4)
  Method 3            32          2.4 (2--3)             --                  --                     --   --
  Method 4            273         6 (5--7)               83                  6 (5--7)               --   --

Median trait values are shown with 25th and 75th percentiles for each clustering cohort. Details for each assay method are provided in [S3 Table](#pmed.1003132.s004){ref-type="supplementary-material"}. **Abbreviations:** BMI, body mass index; DHEAS, dehydroepiandrosterone sulfate; FSH, follicle-stimulating hormone; Glu0, fasting glucose; Ins0, fasting insulin; LH, luteinizing hormone; N, total number; PCOS, polycystic ovary syndrome; SHBG, sex hormone binding globulin; T, testosterone.

The clustering procedure was then repeated in an independent, ungenotyped cohort of 263 NIH PCOS cases diagnosed according to the same criteria as the genotyped clustering cohort ([Table 1](#pmed.1003132.t001){ref-type="table"}). The clustering yielded similar results, with a comparable distribution of reproductive (26%, 68/263, ${\overline{\gamma}}_{C}$ = 0.57), metabolic (39%, 104/263, ${\overline{\gamma}}_{C}$ = 0.46), and indeterminate clusters (35%, 91/263, ${\overline{\gamma}}_{C}$ = 0.40) ([Fig 4](#pmed.1003132.g004){ref-type="fig"}).

![Clustering of ungenotyped PCOS clustering cohort.\
(a) Hierarchical clustering of 263 ungenotyped PCOS cases according to adjusted quantitative traits replicate reproductive (blue), metabolic (red), and unclassified (gray) clusters. Heatmap colors correspond to trait z-scores. (b) PCA plot of ungenotyped PCOS cases replicate results from genotyped cases. (a) Hierarchical clustering of 263 ungenotyped PCOS cases according to adjusted quantitative traits replicate reproductive (blue), metabolic (red), and indeterminate (gray) clusters. Heatmap colors correspond to trait z-scores. (b) PCA plot of ungenotyped PCOS cases replicate results from genotyped cases. BMI, body mass index; DHEAS, dehydroepiandrosterone sulfate; FSH, follicle-stimulating hormone; Glu0, fasting glucose; Ins0, fasting insulin; LH, luteinizing hormone; PC, principal component; PCA, principal component analysis; PCOS, polycystic ovary syndrome; SHBG, sex hormone binding globulin; T, testosterone.](pmed.1003132.g004){#pmed.1003132.g004}

Subtype genetic associations {#sec016}
----------------------------

Genome-wide association testing was performed for each of the 3 subtypes: reproductive, metabolic, and indeterminate ([Table 2](#pmed.1003132.t002){ref-type="table"}). We identified alleles in 4 novel, to our knowledge, loci that were associated with the reproductive PCOS subtype at genome-wide significance (chromosome \[chr\]1 p36.21 *PRDM2*/*KAZN*, *P =* 2.23 × 10^−10^; chr2 q37.3 *IQCA1*, *P =* 2.76 × 10^−9^; chr4 q22.3 *BMPR1B*/*UNC5C*, *P =* 9.71 × 10^−9^; chr5 p14.2--p14.1 *CDH10*, *P =* 1.17 × 10^−8^) and one novel, to our knowledge, locus that was significantly associated with the metabolic subtype (chr2 q24.2--q24.3 *KCNH7*/*FIGN*, *P =* 1.03 × 10^−8^). Association testing on the indeterminate subtype replicated the 11p14.1 *FSHB* locus from our original GWAS \[[@pmed.1003132.ref019]\] ([Table 3](#pmed.1003132.t003){ref-type="table"}; Figs [5](#pmed.1003132.g005){ref-type="fig"} and [6](#pmed.1003132.g006){ref-type="fig"}).

![Genome-wide association results.\
Manhattan plots for (a) reproductive, (b) metabolic, and (c) indeterminate PCOS subtypes. The red horizontal line indicates genome-wide significance (*P* ≤ 1.67 × 10^−8^). Genome-wide significant loci are colored in green and labeled according to nearby gene(s). Quantile--quantile plots with genomic inflation factor, λ~GC~, are shown adjacent to corresponding Manhattan plots. PCOS, polycystic ovary syndrome.](pmed.1003132.g005){#pmed.1003132.g005}

![Risk allele ORs in PCOS and PCOS subtypes.\
ORs with 95% CIs and association P-values from the Stage 1 discovery sample are shown for each subtype-specific risk allele identified in this study relative to the corresponding values for the other subtypes and for PCOS disease status in general (includes all subtypes). Some SNPs were not characterized in certain subtypes because of low allele counts or low imputation confidence. CI, confidence interval; OR, odds ratio; PCOS, polycystic ovary syndrome; SNP, single nucleotide polymorphism.](pmed.1003132.g006){#pmed.1003132.g006}

10.1371/journal.pmed.1003132.t002

###### Demographic characteristics of GWAS subtypes and controls.

![](pmed.1003132.t002){#pmed.1003132.t002g}

                 Reproductive   Metabolic      Indeterminate   Controls
  -------------- -------------- -------------- --------------- ----------
  **N**          207            329            357             4,098
  **Age**        28             28             28              40
  (24--31)       (25--32)       (25--32)       (30--53)        
  **BMI**        25.0           41.1           35.3            25.0
  (22.1--28.0)   (36.4--46.1)   (30.9--39.5)   (21.9--30.3)    

**Abbreviations:** BMI, body mass index; GWAS, genome-wide association study; IQR, interquartile range; N, total number. Data for age and BMI are expressed as median (25th--75th IQR).

10.1371/journal.pmed.1003132.t003

###### Genome-wide significant associations with PCOS subtypes.

![](pmed.1003132.t003){#pmed.1003132.t003g}

  Chr   Mb          Variant      Gene(s)            EA   Stage 1 (Discovery)   Stage 2 (Replication)   P~meta~                                                                                                  
  ----- ----------- ------------ ------------------ ---- --------------------- ----------------------- --------- ------------- ---------------- ------ ------ ------ ------ ------------ --------------- ------ ----------------
  1     *14*.*7*    rs78025940   *PRDM2*/*KAZN*     A    0.02                  3.02                    4.75      2.82--7.98    2.16 × 10^−10^   0.91   --     --     --     --           --              --     2.23 × 10^−10^
  2     *237*.*4*   rs76182733   *IQCA1*            G    0.01                  3.79                    5.68      3.00--10.78   2.67 × 10^−9^    0.84   --     --     --     --           --              --     2.76 × 10^−9^
  4     *96*.*1*    rs17023134   *BMPR1B*/*UNC5C*   G    0.05                  1.62                    3.02      2.06--4.42    1.40 × 10^−8^    0.87   0.06   0.61   1.71   0.98--2.99   7.81 × 10^−2^   0.83   9.71 × 10^−9^
  5     *24*.*7*    rs7735176    *CDH10*            A    0.01                  3.80                    5.09      2.62--9.86    1.14 × 10^−8^    0.93   --     --     --     --           --              --     1.17 × 10^−8^
  2     *164*.*2*   rs55762028   *KCNH7*/*FIGN*     C    0.01                  5.05                    1.86      0.92--3.75    9.17 × 10^−9^    0.96   --     --     --     --           --              --     1.03 × 10^−8^
  11    *30*.*3*    rs10835638   *FSHB*             T    0.16                  0.78                    1.81      1.44--2.27    3.13 × 10^−8^    0.98   0.17   0.77   2.01   1.49--2.70   2.67 × 10^−5^   0.97   4.94 × 10^−12^

Variant information and association statistics are shown for the most strongly associated SNP in each significant locus. Reproductive subtype loci are highlighted in blue, metabolic loci in red, indeterminate loci in gray. **Abbreviations:** Chr, chromosome; CI, confidence interval; EA, effect allele; EAF, effect allele frequency in cases and controls combined; Imp r^2^, imputation r^2^ for imputed SNPs; Mb, megabase position on chromosome; OR, odds ratio; P, stage-specific significance as assessed by logistic regression; PCOS, polycystic ovary syndrome; P~meta~, significance as assessed by sample-size--weighted two-strata meta-analysis, adjusted for genomic inflation factor; SNP, single nucleotide polymorphism; β, effect size from association regression. Cases and controls by stage: Stage 1 = 201 metabolic, 123 reproductive, 231 indeterminate, 2,964 controls; Stage 2 = 128 metabolic, 84 reproductive, 126 indeterminate, 1,134 controls. NOTE: Not all SNPs were genotyped or imputed in both stages.

The strongest association signal with the reproductive subtype appeared in an intergenic region of 1p36.21 579 kb downstream of the *PRMD2* gene and 194 kb upstream from the *KAZN* gene ([Fig 7A](#pmed.1003132.g007){ref-type="fig"}). The lead SNP in the locus (rs78025940; odds ratio \[OR\] = 4.75, 2.82--7.98 95% confidence interval \[CI\], P~1~ = 2.16 × 10^−10^, P~meta~ = 2.23 × 10^−10^) was imputed (r^2^ = 0.91) in Stage 1 only. The SNP was not genotyped in Stage 2. The lead genotyped SNP in the locus (rs16850259) was also associated with the reproductive subtype with genome-wide significance (P~meta~ = 2.14 × 10^−9^) and was genotyped only in Stage 1 (OR = 5.57, 3.24--9.56 95% CI, P~1~ = 2.08 × 10^−9^). In ovarian tissue, the SNPs appear to be centrally located within a large 2 Mb TAD stretching from the *FHAD1* gene to upstream of the *PDPN* gene ([Fig 8](#pmed.1003132.g008){ref-type="fig"}).

![Regional association plots of genome-wide significant loci.\
Regional plots of association (left y-axis) and recombination rates (right y-axis) for the chromosomes (a) 1p36.21, (b) 2q37.3, (c) 4q22.3, (d) 5p14.2--p14.1, (e) 2p24.2--q24.3, and (f) 1p14.1 loci after imputation. The lead SNP in each locus is labeled and marked in purple. All other SNPs are color coded according to the strength of LD with the top SNP (as measured by r^2^ in the European 1000 Genomes data). Imputed SNPs are plotted as circles and genotyped SNPs as squares. LD, linkage disequilibrium; SNP, single nucleotide polymorphism.](pmed.1003132.g007){#pmed.1003132.g007}

![Chromatin interaction map of *PRDM2*/*KAZN* locus.\
(A) Shown is the interaction frequency heatmap from chr1:13,300,000--16,200,000 in ovarian tissue. The color of the heatmap indicates the level of normalized interaction frequencies with blue triangles indicating topological association domains. (B) One-to-all interaction plots are shown for the lead SNP (rs78025940; shown in red) and lead genotyped SNP (rs16850259; shown in blue) as bait. Y-axes on the left and the right measure bias-removed interaction frequency (red and blue bar graphs) and distance-normalized interaction frequency (magenta dots), respectively. (C) The arc representation of significant interactions for distance-normalized interaction frequencies ≥ 2 is displayed relative to the RefSeq-annotated genes in the locus. chr, chromosome; SNP, single nucleotide polymorphism.](pmed.1003132.g008){#pmed.1003132.g008}

The 2q37.3 locus spanned a 50-kb region of strong LD overlapping the 5′ end and promoter region of the *IQCA1* gene ([Fig 7B](#pmed.1003132.g007){ref-type="fig"}). The SNP rs76182733 had the strongest association in this locus (P~meta~ = 2.76 × 10^−9^) with the reproductive subtype. The signal was genotyped only in Stage 1 (OR = 5.68, 3.00--10.78 95% CI, P~1~ = 2.69 × 10^−9^) and was imputed with an imputation r^2^ value of 0.84.

The 4q22.3 locus spanned a 500-kb region of LD, including the 3′ ends of both the *BMPR1B* and *UNC5C* genes ([Fig 7C](#pmed.1003132.g007){ref-type="fig"}). The most strongly associated SNP (rs17023134; P~meta~ = 9.71 × 10^−9^) in the locus was within an intronic region of *UNC5C* and was associated with the reproductive subtype in the Stage 1 discovery sample with genome-wide significance (OR = 3.02, 2.06--4.42 95% CI, P~1~ = 1.40 × 10^−8^) but was not significantly associated in the Stage 2 replication analysis (OR = 1.71, 0.98--2.99 95% CI, P~2~ = 7.8 × 10^−2^). The SNP was imputed with an r^2^ of 0.87 and 0.83 in the Stage 1 and Stage 2 analyses, respectively. The most strongly associated genotyped SNP in the locus (rs10516957) was also genome-wide significant (P~meta~ = 1.46 × 10^−8^) and was located in an intronic region of *BMPR1B*. The genotyped SNP was nominally associated with the reproductive subtype in both the Stage 1 (OR = 2.42, 1.66--3.52 95% CI, P~1~ = 6.72 × 10^−6^) and Stage 2 (OR = 2.40, 1.51--3.82 95% CI, P~2~ = 4.7 × 10^−4^) analyses with nearly identical effect sizes.

In the 5p14.2--p14.1 locus, 83 kb upstream of the *CDH10* gene ([Fig 7D](#pmed.1003132.g007){ref-type="fig"}), 2 adjacent SNPs (rs7735176, rs16893866) in perfect LD were equally associated with the reproductive subtype with genome-wide significance (P~meta~ = 1.17 × 10^−8^). The SNPs were imputed in Stage 1 (OR = 5.09, 2.62--9.86 95% CI, P~1~ = 1.14 × 10^−8^) with an imputation r^2^ of 0.93.

The single locus containing genome-wide significant associations with the metabolic subtype was in an intergenic region of 2q24.2--q24.3 roughly 200 kb downstream from *FIGN* and 500 kb upstream from *KCNH7* ([Fig 7E](#pmed.1003132.g007){ref-type="fig"}). The lead SNP, rs55762028, was imputed in Stage 1 only (OR = 1.86, 0.92--3.75 95% CI, P~1~ = 9.17 × 10^−9^, P~meta~ = 1.03 × 10^−8^). In pancreatic tissue, the lead SNPs appear to be located terminally within a 1.3-Mb TAD encompassing the *FIGN* gene and reaching upstream to the *GRB14* gene ([Fig 9](#pmed.1003132.g009){ref-type="fig"}).

![Chromatin interaction map of *KCHN7*/*FIGN* locus.\
(A) Shown is the interaction frequency heatmap from chr2:162,660,000 to 165,860,000 in pancreatic tissue. The color of the heatmap indicates the level of normalized interaction frequencies with blue triangles indicating topological association domains. (B) One-to-all interaction plots are shown for the lead SNP (rs13401392; shown in blue) and second-leading SNP (rs1394240; shown in red) as bait. Y-axes on the left and the right measure bias-removed interaction frequency (blue and red bar graphs) and distance-normalized interaction frequency (magenta dots), respectively. (C) The arc representation of significant interactions for distance-normalized interaction frequencies ≥ 2 is displayed relative to the RefSeq-annotated genes in the locus. chr, chromosome; SNP, single nucleotide polymorphism.](pmed.1003132.g009){#pmed.1003132.g009}

Association testing on the indeterminate cases replicated the genome-wide significant association in the 11p14.1 *FSHB* locus ([Fig 7F](#pmed.1003132.g007){ref-type="fig"}) identified in our original GWAS (14). The lead SNP (rs10835638; P~meta~ = 4.94 × 10^−12^) and lead genotyped SNP (rs10835646; P~meta~ = 2.75 × 10^−11^) in this locus differed from the index SNPs identified in our original GWAS (rs11031006) and in the PCOS meta-analysis (rs11031005), but both of the previously identified index SNPs were also associated with the indeterminate subgroup with genome-wide significance in this study (rs11031006: P~meta~ = 2.96 × 10^−10^; rs11031005: P~meta~ = 2.91 × 10^−10^) and are in LD with the lead SNP rs10835638 (r^2^ = 0.59) \[[@pmed.1003132.ref040]\]. The other significant signals from our original GWAS \[[@pmed.1003132.ref019]\] were not reproduced in any of the subtype association tests performed in this study ([Table 4](#pmed.1003132.t004){ref-type="table"}).

10.1371/journal.pmed.1003132.t004

###### Previous GWAS association signals in PCOS subtypes.

![](pmed.1003132.t004){#pmed.1003132.t004g}

  Variant      Locus             PCOS                  Reproductive         Metabolic            Indeterminate
  ------------ ----------------- --------------------- -------------------- -------------------- ---------------------
  rs804279     *GATA4*/*NEIL2*   *P =* 8.0 × 10^−10^   *P =* 2.4 × 10^−3^   *P =* 9.9 × 10^−2^   *P =* 3.1 × 10^−3^
  rs10993397   *C9orf3*          *P =* 4.6 × 10^−13^   *P =* 2.3 × 10^−4^   *P =* 6.9 × 10^−5^   *P =* 1.1 × 10^−5^
  rs11031006   *FSHB*            *P =* 1.9 × 10^−8^    *P =* 8.8 × 10^−6^   *P =* 6.6 × 10^−1^   *P =* 3.0 × 10^−10^

Subtype-specific association statistics are shown for each of the SNPs that were significantly associated with PCOS in Hayes and Urbanek and colleagues \[[@pmed.1003132.ref019]\]. *P =* significance as assessed by sample-size--weighted two-strata meta-analysis, adjusted for genomic inflation. **Abbreviations:** GWAS, genome-wide association study; PCOS, polycystic ovary syndrome.

Subtypes in PCOS families {#sec017}
-------------------------

The RF classifier yielded the lowest mean subtype misclassification rate (13.2%) compared to the SVM (13.6%), GMM (17.0%), and QDA (18.1%) models, according to 10-fold cross-validation of the genotyped clustering cohort. Affected women from the family-based cohort were classified accordingly using an RF model. Seventy-three daughters of the 83 affected women from the family-based cohort had complete quantitative trait data available for subtype classification. Seventeen (23.3%) were classified as having the reproductive subtype of PCOS, and 22 (30.1%) were classified as having the metabolic subtype. Of 14 subtyped sibling pairs, only 8 were concordantly classified (57.1%); however, there was only one instance of the reproductive subtype and metabolic subtype occurring within the same nuclear family because the remaining discordant pairs each featured one indeterminate member. The proportion of affected women with one or more of the previously identified \[[@pmed.1003132.ref030]\] deleterious, rare variants in *DENND1A* varied by subtype. Women classified as having the reproductive subtype of PCOS were significantly more likely to carry one or more of the *DENND1A* rare variants compared to other women with PCOS (*P =* 0.03; [Fig 10](#pmed.1003132.g010){ref-type="fig"}). The distribution of affected women and *DENND1A* rare variant carriers are shown relative to the adjusted quantitative trait PCs in [Fig 11](#pmed.1003132.g011){ref-type="fig"}.

![*DENND1A* rare variant carriers by subtype.\
The proportions of affected women with *DENND1A* rare variants in families with PCOS are shown by classified subtype. Women with the reproductive subtype were significantly more likely to carry one or more of the *DENND1A* rare variants compared to other women with PCOS (*P =* 0.03). PCOS, polycystic ovary syndrome.](pmed.1003132.g010){#pmed.1003132.g010}

![PCA of affected women in PCOS families showing *DENND1A* rare variant carriers.\
Affected women in PCOS families are plotted on the first 2 PCs of the adjusted quantitative trait data and colored according to their classified subtype. Markers outlined in bold represent *DENND1A* rare variant carriers. Subtype clusters are shown as 95% concentration ellipses, assuming bivariate normal distributions. The relative magnitude and direction of trait correlations with the PCs are shown with black arrows. BMI, body mass index; DHEAS, dehydroepiandrosterone sulfate; FSH, follicle-stimulating hormone; Glu0, fasting glucose; Ins0, fasting insulin; LH, luteinizing hormone; PC, principal component; PCA, principal component analysis; PCOS, polycystic ovary syndrome; SHBG, sex hormone binding globulin; T, testosterone.](pmed.1003132.g011){#pmed.1003132.g011}

Discussion {#sec018}
==========

It is becoming increasingly clear that common, complex traits such as T2D are a heterogeneous collection of disease subtypes \[[@pmed.1003132.ref008],[@pmed.1003132.ref025],[@pmed.1003132.ref048],[@pmed.1003132.ref049]\]. There is emerging evidence that these subtypes have different genetic architecture \[[@pmed.1003132.ref007],[@pmed.1003132.ref008],[@pmed.1003132.ref025]\]. Consistent with these concepts, we identified reproductive and metabolic subtypes of PCOS by unsupervised hierarchical cluster analysis of quantitative hormonal traits and BMI and found novel, to our knowledge, loci uniquely associated with these subtypes with substantially larger effect sizes than those associated with PCOS disease status in GWAS \[[@pmed.1003132.ref019]--[@pmed.1003132.ref023]\]. We also found that a significantly greater prevalence of women classified with the reproductive subtype of PCOS carried at least one of the previously reported deleterious *DENND1A* rare variants \[[@pmed.1003132.ref030]\] compared with those with other PCOS subtypes. These findings suggest that these subtypes are both genetically distinct as well as more etiologically homogenous \[[@pmed.1003132.ref009]\]. Our findings are in contrast to the recent PCOS GWAS meta-analysis \[[@pmed.1003132.ref022]\] that found that only one of 14 loci was uniquely associated with the NIH phenotype compared to non-NIH Rotterdam phenotypes. These latter findings suggest that the NIH and Rotterdam diagnostic criteria do not identify biologically distinct subtypes of PCOS. There have been previous efforts to subtype PCOS using unsupervised clustering \[[@pmed.1003132.ref026]--[@pmed.1003132.ref029]\], but no subsequent investigation into the biologic relevance of the resulting subtypes using genetic association analyses.

The key traits driving the subtypes were BMI, insulin, SHBG, glucose, LH, and FSH levels. The reproductive subtype was characterized by higher LH and SHBG levels with lower BMI and blood glucose and insulin levels. The metabolic subtype was characterized by higher BMI and glucose and insulin levels with relatively low SHBG and LH levels. The remaining 40% of cases had no distinguishable cluster-wide characteristics, and the mean trait values were between those of the reproductive and metabolic subtypes. The relative trait distributions and results of the PCAs (Figs [2](#pmed.1003132.g002){ref-type="fig"}, [3](#pmed.1003132.g003){ref-type="fig"} and [4B](#pmed.1003132.g004){ref-type="fig"}) showed the reproductive and metabolic subtypes as collections of subjects on opposite ends of a phenotypic spectrum with the remaining indeterminate subjects scattered between the two. Bootstrapping and clustering in an independent cohort revealed that the reproductive and metabolic subtypes were stable and reproducible. When the GWAS was repeated, different susceptibility loci were associated with the reproductive and metabolic subtypes, suggesting that they had distinct genetic architecture. The indeterminate PCOS cases were associated with the reported locus at *FSHB*, but the association signal was stronger than that of our original GWAS \[[@pmed.1003132.ref019]\], suggesting that the indeterminate group was also more genetically homogenous after the reproductive and metabolic subtypes were removed from the analysis.

Two of the loci associated with the reproductive subtype implicate novel biologic pathways in PCOS pathogenesis. The association signal on chr1 appeared downstream of and within the same TAD as the *PRDM2* gene (Figs [7A](#pmed.1003132.g007){ref-type="fig"} and [8](#pmed.1003132.g008){ref-type="fig"}), which is an estrogen receptor coactivator \[[@pmed.1003132.ref050]\] that is highly expressed in the ovary \[[@pmed.1003132.ref051]\] and pituitary gland \[[@pmed.1003132.ref052]\]. In an independent rare variant association study in PCOS families, *PRDM2* demonstrated the fifth strongest gene-level association with altered hormonal levels in PCOS families (*P =* 6.92 × 10^−3^) out of 339 genes tested \[[@pmed.1003132.ref030]\]. PRDM2 binds with ligand-bound estrogen receptor alpha (ERα) to open chromatin at ERα target genes \[[@pmed.1003132.ref050],[@pmed.1003132.ref053]\]. PRDM2 also binds with the retinoblastoma protein \[[@pmed.1003132.ref054]\], which has been found to play an important role in follicular development in granulosa cells \[[@pmed.1003132.ref055],[@pmed.1003132.ref056]\].

The reproductive subtype association in the 4q22.3 locus overlapped with the *BMPR1B* gene, which transcribes a type-I anti-Müllerian hormone (AMH) receptor highly expressed in granulosa cells and in gonadotropin-releasing hormone (GnRH) neurons \[[@pmed.1003132.ref057]\] that regulates follicular development \[[@pmed.1003132.ref058]\]. Bone morphogenetic protein receptor type IB (BMPR1B), also known as ALK6 (activin receptor-like kinase 6), heterodimerizes with the transforming growth factor beta (TGF-β) type-II receptors, including AMH receptor type 2 (AMHR2), and binds AMH and other BMP ligands to initialize TGF-β signaling via the Smad proteins 1, 5, and 8 \[[@pmed.1003132.ref059]\]. *BMPR1B* has been found to mediate the AMH response in ovine granulosa cells \[[@pmed.1003132.ref060]\], and *BMPR1B*-deficient mice are infertile and suffer from a variety of functional defects in the ovary \[[@pmed.1003132.ref061],[@pmed.1003132.ref062]\]. One of the BMPR1B ligand genes, *BMP6*, had the third-strongest gene-level association with altered hormonal levels (*P* = 4.00 × 10^−3^) out of 339 genes tested in our rare variant association study in PCOS families \[[@pmed.1003132.ref030]\]. Collectively, these results make *BMPR1B* a compelling candidate gene in PCOS pathogenesis. These findings also support our sequencing studies that have implicated pathogenic variants in the AMH signaling pathway in PCOS \[[@pmed.1003132.ref063],[@pmed.1003132.ref064]\].

The nature of the potential involvement in PCOS is less clear for the other loci associated with the reproductive subtype. The 2q37.3 locus overlapped with the promoter region of the *IQCA1* gene. Its function in humans is not well characterized, but *IQCA1* is highly expressed in the pituitary gland \[[@pmed.1003132.ref052]\]. The 5p14.2--p14.1 locus overlapped the promoter region of the *CDH10* gene. *CDH10* is almost exclusively expressed in the brain \[[@pmed.1003132.ref051]\] and is putatively involved in synaptic adhesions, axon outgrowth, and guidance \[[@pmed.1003132.ref065]\].

The lone significant association signal with the metabolic subtype was located in an intergenic region 200--280 kb downstream of the *FIGN* gene, 490--570 kb upstream of *KCNH7*. *KCNH7* encodes a voltage-gated potassium channel (subfamily H member 7, alias ERG3 \[early growth response protein 3\]). *KCNH7* is primarily expressed in the nervous system \[[@pmed.1003132.ref066]\] but has been found in murine islet cells \[[@pmed.1003132.ref067],[@pmed.1003132.ref068]\]. *FIGN* encodes fidgetin, a microtubule-severing enzyme most highly expressed in the pituitary gland and ovary \[[@pmed.1003132.ref051]\]. A genetic variant in *FIGN* was found to reduce the risk of congenital heart disease in Han Chinese by modulating transmembrane folate transport \[[@pmed.1003132.ref069],[@pmed.1003132.ref070]\]. The TAD encompassing the association signal in this locus includes *FIGN* and extends upstream to the *GRB14* gene ([Fig 8](#pmed.1003132.g008){ref-type="fig"}). *GRB14* plays an important role in insulin receptor signaling \[[@pmed.1003132.ref071],[@pmed.1003132.ref072]\] and has been associated with T2D in GWAS \[[@pmed.1003132.ref073]\]. Given the various metabolic associations for the genes in this chromosomal region, it is plausible that causal variants in this locus could impact a combination of these genes.

Despite evidence linking neighboring genes to PCOS pathways in each of the aforementioned loci, it remains possible, of course, that other, more distant genes in LD underlie the association signals. Causal variants are often up to 2 Mb away from the associated SNP, not necessarily in the closest gene \[[@pmed.1003132.ref074]\]. Fine-mapping and functional studies are needed in order to confirm the causal variants in each of these loci. In addition, the sample sizes for the subtype GWAS were small, some of the associations were based only on imputed SNPs in Stage 1, and a replication association study has not yet been performed. However, the aforementioned functional evidence for several of the loci---particularly for *PRDM2* and *BMPR1B*---support the validity of their associations. Further, the fact that one of the genes associated with the reproductive subtype, *PRDM2*, was associated with PCOS quantitative traits in our family-based analysis \[[@pmed.1003132.ref030]\] does represent a replication of this signal by an independent analytical approach. Nevertheless, our genetic association results should be considered preliminary.

The effect sizes of the subtype alleles, particularly those associated with the reproductive subtype (OR 3.02--5.68) ([Table 3](#pmed.1003132.t003){ref-type="table"}), were substantially greater than the effects (OR 0.70--1.51) observed for alleles associated with PCOS diagnosis in previous GWAS \[[@pmed.1003132.ref019]--[@pmed.1003132.ref023]\]. In general, there is an inverse relationship between allele frequency and effect size \[[@pmed.1003132.ref001]\] because alleles with larger phenotypic effects are subject to purifying selection and, therefore, occur less frequently in the population \[[@pmed.1003132.ref075],[@pmed.1003132.ref076]\]. Accordingly, in contrast to the common variants (effect allele frequency \[EAF\] \> 0.05) associated with PCOS in previous GWAS \[[@pmed.1003132.ref019]--[@pmed.1003132.ref023]\], the alleles associated with the subtypes were all of low frequency (EAF 0.01--0.05; [Table 3](#pmed.1003132.t003){ref-type="table"}). However, given the limited cohort sizes in this study, the subtype association testing did not have adequate power to detect associations with more modest effect sizes, such as those from our previous GWAS \[[@pmed.1003132.ref019]\]. It is also possible that the large effect sizes were somewhat inflated by the so-called "winner's curse" \[[@pmed.1003132.ref077],[@pmed.1003132.ref078]\], but they nonetheless suggest that the subtypes were more genetically homogeneous than PCOS diagnosis in general.

In applying a subtype classifier to our family-based cohort, we found 12 affected sibling pairs in which at least one of the daughters was classified with the reproductive or metabolic subtype. Six of these sibling pairs were classified with the same subtype. There was only one discordant pairing of the reproductive subtype with the metabolic subtype. This further suggests that the reproductive and metabolic subtypes are genetically distinct in their origins. The greater prevalence of *DENND1A* rare variant carriers observed in women with the reproductive subtype in the family-based cohort implicates this gene in the pathogenesis of this subtype. *DENND1A* is known to regulate androgen biosynthesis in the ovary \[[@pmed.1003132.ref079],[@pmed.1003132.ref080]\]; therefore, we would expect *DENND1A*-mediated PCOS to be more closely associated with the reproductive subtype of PCOS. However, we did not find an association between any *DENND1A* alleles and the reproductive subtype in the subtype GWAS, perhaps because of allelic heterogeneity or our limited power to detect associations with more modest effect sizes.

We only studied women with PCOS as defined by the NIH diagnostic criteria. Future studies will investigate whether similar reproductive and metabolic clusters are present in non-NIH Rotterdam PCOS cases. In particular, it is possible that there will be no metabolic subtype in non-NIH Rotterdam PCOS cases because these phenotypes have minimal metabolic risk \[[@pmed.1003132.ref081],[@pmed.1003132.ref082]\]. Indeed, in a previous effort to identify phenotypic subtypes in Rotterdam PCOS cases \[[@pmed.1003132.ref029]\], the cluster that most closely resembled the reproductive subtype represented the largest proportion of PCOS women at 44%, of whom only 78% met the NIH criteria for PCOS, whereas the cluster that most closely resembled the metabolic subtype constituted only 12% of the total sample, but 98% met the NIH diagnostic criteria. Furthermore, trait distributions may vary among women with PCOS from different geographic locations, such as in some of the sites excluded from our analysis because of incomplete quantitative trait data. For example, European PCOS cases have a lower prevalence of obesity compared to US PCOS cases \[[@pmed.1003132.ref083]\]. Because of the within-cohort normalization of quantitative traits prior to clustering, our method is well-suited for identifying subsets of cases within populations, but therefore, it may not be suitable for directly comparing subtype membership between populations.

Our clustering cohorts included only US-based women of European ancestry. It will be of considerable importance to investigate whether subtypes are present in women with PCOS of other ancestries and geographic regions. Women with PCOS of diverse races and ethnicities have similar reproductive and metabolic features \[[@pmed.1003132.ref084]--[@pmed.1003132.ref086]\]. However, there are differences in the severity of the metabolic defects due to differences in the prevalence of obesity \[[@pmed.1003132.ref083]\], as well as to racial/ethnic differences in insulin sensitivity \[[@pmed.1003132.ref087],[@pmed.1003132.ref088]\]. Furthermore, the susceptibility loci associated with subtypes in other ancestry groups may differ because the low frequency and large effect size of the variants associated with the reproductive subtype in our European cohort suggests these variants are of relatively recent origin and therefore may be population-specific \[[@pmed.1003132.ref001],[@pmed.1003132.ref089],[@pmed.1003132.ref090]\].

While the bootstrapping and clustering in an independent cohort demonstrated that the subtypes were reproducible, the Jaccard scores were relatively modest, with only the reproductive subtype yielding a mean Jaccard coefficient ${\overline{\gamma}}_{C}$ \> 0.6. At least part of this outcome was likely due to the fact that all traits were fitted to a normal distribution using an inverse normal transformation prior to clustering. This transformation was done in order to prevent outliers from dictating cluster formations but also likely resulted in greater cluster overlap. Consequently, the metabolic and reproductive clusters we identified appear to represent opposite ends of a phenotypic spectrum with imperfect delineation. This spectrum, however, aligns with the known pathophysiology of PCOS and is bolstered by our genetic association findings. Our approach, therefore, appears to be a more reliable way of identifying subgroups of PCOS cases who have been noted in the literature \[[@pmed.1003132.ref091]\] but have previously been defined using only a single trait like BMI \[[@pmed.1003132.ref092]--[@pmed.1003132.ref095]\] or by diagnostic criteria that do not reflect the genetic heterogeneity of the disorder \[[@pmed.1003132.ref022]\]. Perhaps future studies that use clustering to identify reproductive and metabolic subtypes in PCOS can omit nondistinguishing traits such as DHEAS and T in an effort to reduce noise and improve subtype delineation and reproducibility.

Our study provides support for the hypothesis that PCOS is in fact a heterogeneous disorder with different underlying biological mechanisms. As a consequence, grouping women with PCOS under a single diagnosis may be counterproductive because distinct disease subtypes will likely benefit from different interventions.

In conclusion, using an unsupervised clustering approach featuring quantitative hormonal and anthropometric data, we identified reproductive and metabolic subtypes of PCOS that appeared to have distinct genetic architecture. The genomic loci that were significantly associated with either of these subtypes include a number of new, to our knowledge, highly plausible PCOS candidate genes. Moreover, our results demonstrate that precise phenotypic delineation, resulting in more homogeneous subsets of affected individuals, can be more powerful and informative than increases in sample size for genetic association studies. Our findings indicate that further study into the genetic heterogeneity of PCOS is warranted and could lead to a transformation in the way PCOS is classified, studied, and treated.
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###### STREGA checklist.

(DOCX)

###### 

Click here for additional data file.

###### GWAS cohorts used in cluster analysis.

The cohorts from the Hayes, Urbanek, and colleagues PCOS GWAS and corresponding numbers of samples that were included in the clustering analysis are shown by GWAS cohort, adapted from Hayes, Urbanek, and colleagues. \[[@pmed.1003132.ref019]\]: Table 1 and Supplemental Data Tables 9 and 10. GWAS, genome-wide association study; PCOS, polycystic ovary syndrome.

(DOCX)

###### 

Click here for additional data file.

###### Age and BMI distributions for subjects excluded from cluster analysis.

Median age and BMI values are shown with the 25th and 75th percentiles for the subjects included in the cluster analysis and for those from the same GWAS cohorts who were excluded because of missing quantitative trait data. Distributions were compared using unpaired Wilcoxon rank--sum tests. P-values are unadjusted. BMI, body mass index; GWAS, genome-wide association study.

(XLSX)

###### 

Click here for additional data file.

###### Assays used to measure quantitative traits.

Assays used to measure quantitative trait levels are listed by trait, then by site and methodology combination. Unless otherwise noted, kits were used per the manufacturer's instructions. \*Calibrated to WHO 1st International Standard \#95/560. ^a^Diagnostic Products Corporation (DPC) (Los Angeles, CA, USA) \[Note: In April 2006, DPC was acquired by Siemens Medical Solutions USA, Inc. (Malvern, PA, USA)\]. ^b^Diagnostic Systems Laboratories, Inc. (DSL) (Webster, TX, USA) \[Note: In October 2005, DSL was acquired by Beckman Coulter (Brea, CA, USA)\]. ^c^Siemens Medical Solutions USA, Inc. (Malvern, PA, USA). ^d^Beckman Coulter, Inc. (Brea, CA, USA) \[Note: In June 2011, Beckman Coulter was acquired by Danaher Corporation (Washington, DC, USA)\]. ^e^Analox Instruments Ltd. (London, UK). ^f^Linco Research, Inc. (St. Charles, MO, USA). ^g^American Laboratory Products Company (ALPCO) (Salem, NH, USA). BWH, Brigham and Women\'s Hospital; DHEAS, dehydroepiandrosterone sulfate; ELISA, enzyme-linked immunosorbent assay; FSH, follicle-stimulating hormone; GO, Glucose; G0, fasting glucose; HMC, Pennsylvania State Milton S. Hershey Medical Center; IRMA, immunoradiometric assay; I0, fasting insulin; LH, luteinizing hormone; NU, Northwestern University; RIA, radioimmunoassay; SHBG, sex hormone binding globulin; T, testosterone; UVA, University of Virginia.

(XLSX)

###### 

Click here for additional data file.

###### Quantitative traits in genotyped PCOS cohort by cluster.

Median trait values are shown with 25th and 75th percentiles for each clustering subtype. Details for each assay method are provided in [S3 Table](#pmed.1003132.s004){ref-type="supplementary-material"}. BMI, body mass index; DHEAS, dehydroepiandrosterone sulfate; FSH, follicle-stimulating hormone; G0, fasting glucose; I0, fasting insulin; LH, luteinizing hormone; N, total number; PCOS, polycystic ovary syndrome; SHBG, sex hormone-binding globulin; T, testosterone.

(XLSX)

###### 

Click here for additional data file.

###### Subtypes of Stage 1 GWAS samples.

Subtypes are provided for each of the 555 Stage 1 GWAS samples included in the clustering analysis according to their dbGaP SUBJIDs. dbGaP, database of Genotypes and Phenotypes; GWAS, genome-wide association study; SUBJID, subject ID.

(TXT)

###### 

Click here for additional data file.
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AMH

:   anti-Müllerian hormone

ARL14EP

:   ADP ribosylation factor like GTPase 14 effector protein

AS1

:   antisense RNA 1

BMI

:   body mass index

BMPR1B

:   bone morphogenetic protein receptor type IB

CASP9

:   caspase 9

CDH10

:   cadherin 10

CELA2

:   chymotrypsin like elastase 2

CI

:   confidence interval

COBLL1

:   cordon-bleu WH2 repeat protein like 1

CTRC

:   chymotrypsin C

C1orf195

:   chromosome 1 open reading frame 195

dbGaP

:   database of Genotypes and Phenotypes

DDI2

:   DNA damage inducible 1 homolog 2

DENND1A

:   DENN domain containing 1A

DHEAS

:   dehydroepiandrosterone sulfate

DNAJC16

:   DnaJ heat shock protein family (Hsp40) member C16

DPP4

:   dipeptidyl peptidase 4

EAF

:   effect allele frequency

EFHD2

:   EF-hand domain family member D2

ERG3

:   early growth response protein 3

ERα

:   estrogen receptor α

FAP

:   fibroblast activation protein alpha

FBLIM1

:   filamin binding LIM protein 1

FHAD1

:   forkhead associated phosphopeptide binding domain 1

FIGN

:   fidgetin

FLJ37453

:   uncharacterized LOC729614

FSH

:   follicle-stimulating hormone

FSHB

:   follicle stimulating hormone subunit beta

GCA

:   grancalcin

GCG

:   glucagon

Glu0

:   fasting glucose

GMM

:   Gaussian mixed model

GnRH

:   gonadotropin-releasing hormone

GRB14

:   growth factor receptor bound protein 14

GWAS

:   genome-wide association study

HA

:   hyperandrogenism

Hi-C

:   chromatin conformation capture

IFIH1

:   interferon induced with helicase C domain 1

Ins0

:   fasting insulin

IQCA1

:   IQ motif containing with AAA domain 1

IQR

:   interquartile range

KAZN

:   kazrin, periplakin interacting protein

KCNH7

:   potassium voltage-gated channel subfamily H member 7

LD

:   linkage disequilibrium

LH

:   luteinizing hormone

LOC

:   uncharacterized non-coding RNA

LRRC38

:   leucine rich repeat containing 38

MAC

:   minor allele count

MAF

:   minor allele frequency

MIR5096

:   microRNA 5096

MPPED2

:   metallophosphoesterase domain containing 2

NIH

:   National Institutes of Health

OD

:   ovulatory dysfunction

OR

:   odds ratio

PC

:   principal component

PCA

:   principal component analysis

PCOM

:   polycystic ovarian morphology

PCOS

:   polycystic ovary syndrome

PDPN

:   podoplanin

PLEKHM2

:   pleckstrin homology and RUN domain containing M2

PPCOSII

:   Pregnancy in PCOS II

PRAMEF

:   preferentially expressed antigen in melanoma family member

PRDM2

:   PR/SET domain 2

PRDM9

:   PR/SET domain 9

QDA

:   quadratic discriminant analysis

RF

:   random forest

RSC1A1

:   regulator of solute carriers 1

SHBG

:   sex hormone binding globulin

SLC25A34

:   solute carrier family 25 member 34

SLC38A11

:   solute carrier family 38 member 11

SNORA70F

:   small nucleolar RNA, H/ACA box 70F

SNP

:   single nucleotide polymorphism

SPEN

:   spen family transcriptional repressor

STREGA

:   Strengthening the Reporting of Genetic Association Studies

SVM

:   support vector machine

T

:   testosterone

TAD

:   topologically associating domain

TGF-β

:   transforming growth factor beta

TMEM

:   transmembrane protein

T2D

:   type 2 diabetes

UNC5C

:   unc-5 netrin receptor C

UQCRHL

:   ubiquinol-cytochrome c reductase hinge protein like
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28 Jan 2020

Dear Dr. Dapas,

Thank you very much for submitting your manuscript \"Phenotypic clustering reveals distinct subtypes of polycystic ovary syndrome with novel genetic associations\" (PMEDICINE-D-19-03066) for consideration at PLOS Medicine.

Your paper was evaluated by a senior editor and discussed among all the editors here. It was also discussed with an academic editor with relevant expertise, and sent to four independent reviewers, including a statistical reviewer. The reviews are appended at the bottom of this email and any accompanying reviewer attachments can be seen via the link below:

\[LINK\]

In light of these reviews, I am afraid that we will not be able to accept the manuscript for publication in the journal in its current form, but we would like to consider a revised version that addresses the reviewers\' and editors\' comments. Obviously we cannot make any decision about publication until we have seen the revised manuscript and your response, and we plan to seek re-review by one or more of the reviewers.

Of particular importance, in order for us to consider a revised submission we request that you please upload the relevant code to GitHub or a similar accessible repository, including an accompanying README document, as noted by Reviewer 2.

In revising the manuscript for further consideration, your revisions should address the specific points made by each reviewer and the editors. Please also check the guidelines for revised papers at <http://journals.plos.org/plosmedicine/s/revising-your-manuscript> for any that apply to your paper. In your rebuttal letter you should indicate your response to the reviewers\' and editors\' comments, the changes you have made in the manuscript, and include either an excerpt of the revised text or the location (eg: page and line number) where each change can be found. Please submit a clean version of the paper as the main article file; a version with changes marked should be uploaded as a marked up manuscript.

In addition, we request that you upload any figures associated with your paper as individual TIF or EPS files with 300dpi resolution at resubmission; please read our figure guidelines for more information on our requirements: <http://journals.plos.org/plosmedicine/s/figures>. While revising your submission, please upload your figure files to the PACE digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <PLOSMedicine@plos.org>.

We expect to receive your revised manuscript by Feb 11 2020 11:59PM. Please email us (<plosmedicine@plos.org>) if you have any questions or concerns.

\*\*\*Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.\*\*\*

We ask every co-author listed on the manuscript to fill in a contributing author statement, making sure to declare all competing interests. If any of the co-authors have not filled in the statement, we will remind them to do so when the paper is revised. If all statements are not completed in a timely fashion this could hold up the re-review process. If new competing interests are declared later in the revision process, this may also hold up the submission. Should there be a problem getting one of your co-authors to fill in a statement we will be in contact. YOU MUST NOT ADD OR REMOVE AUTHORS UNLESS YOU HAVE ALERTED THE EDITOR HANDLING THE MANUSCRIPT TO THE CHANGE AND THEY SPECIFICALLY HAVE AGREED TO IT. You can see our competing interests policy here: <http://journals.plos.org/plosmedicine/s/competing-interests>.

Please use the following link to submit the revised manuscript:

<https://www.editorialmanager.com/pmedicine/>

Your article can be found in the \"Submissions Needing Revision\" folder.

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see <http://journals.plos.org/plosmedicine/s/submission-guidelines#loc-methods>.

Please ensure that the paper adheres to the PLOS Data Availability Policy (see <http://journals.plos.org/plosmedicine/s/data-availability>), which requires that all data underlying the study\'s findings be provided in a repository or as Supporting Information. For data residing with a third party, authors are required to provide instructions with contact information for obtaining the data. PLOS journals do not allow statements supported by \"data not shown\" or \"unpublished results.\" For such statements, authors must provide supporting data or cite public sources that include it.

We look forward to receiving your revised manuscript.

Sincerely,

Caitlin Moyer, Ph.D.

Associate Editor

PLOS Medicine

[plosmedicine.org](http://plosmedicine.org)

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

Requests from the editors:

1\. Title: Please revise your title according to PLOS Medicine\'s style. Your title must be nondeclarative and not a question. It should begin with main concept if possible. \"Effect of\" should be used only if causality can be inferred, i.e., for an RCT. Please place the study design (\"A randomized controlled trial,\" \"A retrospective study,\" \"A modelling study,\" etc.) in the subtitle (ie, after a colon).

We suggest: "Novel genetic associations of distinct subtypes of polycystic ovary syndrome: An unsupervised hierarchical clustering analysis" or similar.

2\. Data Availability: PLOS Medicine requires that the de-identified data underlying the specific results in a published article be made available, without restrictions on access, in a public repository or as Supporting Information at the time of article publication, provided it is legal and ethical to do so. If the data are not freely available, please include an appropriate contact (web or email address) for inquiries (please note that this cannot be a study author). Please see the policy at:

<http://journals.plos.org/plosmedicine/s/data-availability>

and FAQs at

<http://journals.plos.org/plosmedicine/s/data-availability#loc-faqs-for-data-policy>

3\. Prospective data analysis plan: Did your study have a prospective protocol or analysis plan? Please state this (either way) early in the Methods section. If your study has an associated prospective protocol or analysis plan, please include the file as supporting information, and reference it in the Methods.

a\) If a prospective analysis plan (from your funding proposal, IRB or other ethics committee submission, study protocol, or other planning document written before analyzing the data) was used in designing the study, please include the relevant prospectively written document with your revised manuscript as a Supporting Information file to be published alongside your study, and cite it in the Methods section. A legend for this file should be included at the end of your manuscript.

b\) If no such document exists, please make sure that the Methods section transparently describes when analyses were planned, and when/why any data-driven changes to analyses took place.

c\) In either case, changes in the analysis---including those made in response to peer review comments---should be identified as such in the Methods section of the paper, with rationale.

4\. Abstract: Methods and Findings: Please include some information on the population, years during which the study took place, and the study's main outcome measures.

5\. Abstract: Conclusions: Line 58: The term "stable" in this sentence is unclear, please revise.

6\. Author Summary: At this stage, we ask that you include a short, non-technical Author Summary of your research to make findings accessible to a wide audience that includes both scientists and non-scientists. The Author Summary should immediately follow the Abstract in your revised manuscript. This text is subject to editorial change and should be distinct from the scientific abstract. Please see our author guidelines for more information: <https://journals.plos.org/plosmedicine/s/revising-your-manuscript#loc-author-summary>

7\. Methods: Thank you for including your Ethics Statement on the manuscript submission form ("The study was approved by the Institutional Review Board of Northwestern University Feinberg School of Medicine (\#STU00008096). All subjects gave written informed consent before study."), can you please also include this information in the methods?

8\. Methods: Please present a table of summary/demographic information for the various cohorts- the information that is in S1 Table should be moved to the main text.

9\. Results: "PCOS Subtypes": For the percentages reported here, please present numerators and denominators.

10\. Discussion: Please present and organize the Discussion as follows: a short, clear summary of the article\'s findings; what the study adds to existing research and where and why the results may differ from previous research; strengths and limitations of the study; implications and next steps for research, clinical practice, and/or public policy; one-paragraph conclusion.

11\. Figure 2: The small inset frequency histogram is difficult to read, particularly the Y axis. Can you please provide any description of the clustering relationships among the traits displayed on the left side of the chart?

12\. Figure 5: Panel "a" is difficult to read, in particular the text of the histogram is very small (and appears to be missing an X axis label). Please increase the size of the text. Please define all abbreviations used in the figure legend.

13\. Figure 6: Please increase the size of the Y axis labels. Please increase the size of the QQ plots, they are too small to read.

14\. Figure 7: The left-hand side axis is cutting off one of the CI bars for the rs55762028 risk allele.

15\. Figure 8, 9, 10: Please increase the text size on the graphs.

16\. Table 1: Please define abbreviations for "Chr" and "Mb" in the legend.

17\. References: Please use square brackets for in-text citations, like this: \[1\].

18\. Checklist: Please report your study according to the relevant guideline (STREGA or STROBE may be most appropriate), which can be found here: <http://www.equator-network.org/>

Please include the completed STROBE/STREGA checklist as Supporting Information. When completing the checklist, please use section/paragraph numbers rather than page numbers. Please add the following statement, or similar, to the Methods: \"This study is reported as per the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guideline (S1 Checklist).\"

Comments from the reviewers:

Reviewer \#1: In\" Phenotypic clustering reveals distinct subtypes of polycystic ovary syndrome with novel genetic associations\" the authors describe a two step genetic and hormonal analysis to bettern understand underlying genetic changes in women with two different phenotypes of PCOS. The authors initially performed a Unsupervised hierarchical cluster analysis of anthropometric, reproductive, and metabolic traits in a genotyped discovery cohort of 893 PCOS cases and identified a reproductive (High LH and SHBG) and a metabolic phenotype. These clusters were confirmed in a secondary cohort and a bootstrapped sample. GWAS was then performed in many of these samples and in healthy controls and found 4 alleles identified with the reproductive and 1 with the metabolic phenotype. Additional study was performed from a cohort of familial clustered PCOS individuals.

Overall the study is vell-designed, well-powered and well-presented. The results add to literature of trying to understand a genetic basis for PCOS.

Abstract: The results for the unclustered 293 aren\'t presented? The 73 family cluster results were a surprise- should have been listed with other 2 cohorts at tope of methods.

Figure 1, if possible to put reproductive, metabolic and indeterminate at the top of the heatmap, it would make it easier for the reader to interpret.

Since total T reflect the influence of SHBG, which is different between the groups, it would be of interest to see if FAI is a better indicator, ie Fig 3

Axses on Figure 8 need to be larger

Reviewer \#2: The manuscript investigates the presence of molecular subtypes in polycystic ovary syndrome (PCOS). The authors apply unsupervised learning to phenotypic quantitative traits and identify three distinct clusters, which they call \"reproductive\", \"metabolic\" and \"intermediate\". The first two are subsequently fed to a Genome-Wide Association Study (GWAS) to look for distinctive genetic variants underlying the corresponding population groups. Results suggest genetic heterogeneity and distinct disease subtypes that get classified under the same PCOS umbrella.

Overall, this is a very well-written paper with sound methodology and fair presentation. The statistical analyses are well motivated, and conclusions are evaluated for robustness using standard tools like bootstrap resampling, multiple hypothesis testing correction, replication in a separate validation cohort, and reporting of confidence regions. The few places where the tests are underpowered (i.e., GWAS), the results are presented through a realistic lens. There are only a few relatively minor criticisms of the work.

First, there is no accompanying code, which makes the analyses irreproducible. My suggestion is to create a code repository (e.g., on GitHub) and upload the scripts used for clustering, GWAS and machine learning analyses. A README detailing how to access the datasets used by the code must be included.

There is a slight disconnect between Introduction and the presented findings. Examples provided during the opening (lines 65-71) give an impression that the authors are investigating genetically heterogeneous subtypes that give rise to a convergent phenotype. However, the first step of the analysis is a phenotypic separation (i.e., divergence) of samples into clusters. This doesn\'t invalidate the study, but I think a minor change in the opening angle could be appropriate.

In several places, the analysis considers projections of data onto the first k principal components. This includes outlier detection (line 190) and batch adjustment (line 200). The authors need to show that the number of components considered (two and three, respectively) captures the sufficient amount of signal in the data. The standard way of doing this is via Horn\'s Parallel Analysis (doi:10.1007/bf02289447) where the data is randomly permuted along each dimension, and the resulting principal component variance of the scrambled data is compared to the original.

I would like to see more justification for why the hierarchical clustering was collapsed to only three subtypes. To me, it seems that there\'s a fourth cluster within the \"Intermediate\" subtype, characterized by high levels of ovarian theca cell testosterone (T) production. This is visually supported by the distinct pattern in the heatmap (Fig 2), as well as a strong alignment of T with the second principal component in both cohorts (Figs 4 and 5). If Jaccard coefficient was used to make this decision, then the authors need to also report coefficients associated with the two-cluster solution (\"reproductive\" and \"metabolic + intermediate\") and the four-cluster solution (\"reproductive\", \"metabolic\", \"T-high intermediate\" and \"T-low intermediate\"), highlighting that the three-cluster solution yields an inflection point.

Please include a short statement about whether there was general agreement between the various classification methods (lines 220-225). Large discrepancy in performance may indicate that subtype classifications are not robust, and a further look at the data properties may be required to motivate the proper method choice (e.g., there may be strong nonlinear relationships between input variables that warrant the use of random forests).

Lastly, I agree with the authors that the GWAS analyses may be underpowered. Given that significant signal from previous GWAS was not observed in any of the subtypes (line 392), and that there is very limited replication of hits in the Stage 2 cohort (Table 1), I feel that a number of the hits identified may actually be spurious (in particular, BMPR1B/UNC5C and CDH10). However, the authors readily admit that the GWAS findings are preliminary and provide some Hi-C data and literature-backed justification for why and how the identified variants may regulate PCOS pathways.

Minor comments:

-Table S1 provides only the summary statistics. In line with the earlier comment about reproducibility, it would be helpful to include detailed instructions on how the raw data was accessed.

-Please provide reasoning behind the r\^2 threshold of 0.8 on line 194. It seems a bit high given the sample size.

-Double-check the significance of FSH in Fig3. Visually, it seems the median of each group falls within the interquartile range of the other group. I am surprised this leads to a significant distinction, especially after Bonferroni correction.

-Figure 3 caption: missing definition of T.

Reviewer \#3: The ms by Dapas et al suggests that the diagnostic rubric \"polycystic ovarian syndrome\" is heterogeneous in clinical presentation and that the phenotypic heterogeneity has genetic underpinnings. The notion that PCOS is not one diagnostic category is an overdue concept. The authors of the present ms have presented data to support the notion that anovulation due to PCOS is more complex that previously appreciated.

Accepting that the analytic methodology is sufficiently rigorous to support the authors\' analysis and conclusions, parsing PCOS suggests that clinicians need to refine treatment approaches. Women with PCOS are poorly served by being lumped into a single diagnostic entity as doing so then suggests that all women with PCOS need similar interventions.

Reviewer \#4: The authors of this paper have undertaken a study to see whether they could identify different phenotypical PCOS subgroups with a different genetic background. This hypothesis was driven by the fact that a recent GWAS didn\'t show any differences between women with PCOS diagnosed according to different diagnostic criteria. Indeed this suggests that diagnostic criteria currently used are not adequately identifying phenotypes that might matter in a clinical sense. In order to do so they first undertook a unsupervised cluster analysis in order to identify different subtypes of PCOS. Thereafter they did a GWAS on the different subtypes and identified new loci associated with the newly defined phenotypes. They also did a similar analysis in in a family based PCOS cohort and showed that a rare DENND1A variant was significantly more often found in the reproductive phenotype compared to the metabolic phenotype.

The study is well designed and the authors have to be congratulated with this large and innovative approach. This is a complex and laborious endeavour. Methods seem to be appropriate and statistics that were applied, although complex, are similarly adequate. The manuscript reads well and the arguing is consistent and sound. The paper is well written and the figures and tables are easy to read and appropriately summarise the findings of the study.

I have only one major issue that is:

That is, although the Jaccard indices, depicting that the phenotypes are really distinct, are not that high to claim that with the certainty of how it is written down in the results. In fact there is only one value that is really above 0.6 i.e. the one from the phenotype that is associated with the reproductive trait. This should be mentioned in more detail in the discussion. Although this constitutes a limitation the study is still reporting valid an interesting data and provides a novel view of how to define PCOS.

There is also a few minor issues such as:

NIH diagnosed women with PCOS constitute a subset of the whole population diagnosed according to the Rotterdam criteria. This should be mentioned in the M&M section.

Was there any effort made to compare (in terms of general characteristics such as age, BMI etc.) the group of 893 individuals and the ones from whom not a complete set quantitative trait date were available. May be it is also worthwhile to show how many out of each cohort were selected for this analysis.

I was wondering how many women were using OCP or other hormones until 3 months prior to actual phenotyping. Knowing that some effects of especially OCP\'s might last longer than 3 months this might have impacted on the data. For instance Testosterone levels and SHBG levels might very well be suppressed for quite some time after discontinuing OCP\'s. If only a limited number of women would have been using OCP\'s until recently this would make the data more solid than they already are. This should be mentioned too in case these data are available.

Any attachments provided with reviews can be seen via the following link:

\[LINK\]

10.1371/journal.pmed.1003132.r002
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Decision Letter 1

Moyer

Caitlin

Senior Editor

© 2020 Caitlin Moyer

2020

Caitlin Moyer

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

17 Apr 2020

Dear Dr. Dapas,

Thank you very much for re-submitting your manuscript \"Distinct subtypes of polycystic ovary syndrome with novel genetic associations: an unsupervised, phenotypic clustering analysis\" (PMEDICINE-D-19-03066R1) for review by PLOS Medicine.

I have discussed the paper with my colleagues and the academic editor and it was also seen again by two reviewers. I am pleased to say that provided the remaining editorial and production issues are dealt with we are planning to accept the paper for publication in the journal.

The remaining issues that need to be addressed are listed at the end of this email. Any accompanying reviewer attachments can be seen via the link below. Please take these into account before resubmitting your manuscript:

\[LINK\]

Our publications team (<plosmedicine@plos.org>) will be in touch shortly about the production requirements for your paper, and the link and deadline for resubmission. DO NOT RESUBMIT BEFORE YOU\'VE RECEIVED THE PRODUCTION REQUIREMENTS.

\*\*\*Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.\*\*\*

In revising the manuscript for further consideration here, please ensure you address the specific points made by each reviewer and the editors. In your rebuttal letter you should indicate your response to the reviewers\' and editors\' comments and the changes you have made in the manuscript. Please submit a clean version of the paper as the main article file. A version with changes marked must also be uploaded as a marked up manuscript file.

Please also check the guidelines for revised papers at <http://journals.plos.org/plosmedicine/s/revising-your-manuscript> for any that apply to your paper. If you haven\'t already, we ask that you provide a short, non-technical Author Summary of your research to make findings accessible to a wide audience that includes both scientists and non-scientists. The Author Summary should immediately follow the Abstract in your revised manuscript. This text is subject to editorial change and should be distinct from the scientific abstract.

We expect to receive your revised manuscript within 1 week. Please email us (<plosmedicine@plos.org>) if you have any questions or concerns.

We ask every co-author listed on the manuscript to fill in a contributing author statement. If any of the co-authors have not filled in the statement, we will remind them to do so when the paper is revised. If all statements are not completed in a timely fashion this could hold up the re-review process. Should there be a problem getting one of your co-authors to fill in a statement we will be in contact. YOU MUST NOT ADD OR REMOVE AUTHORS UNLESS YOU HAVE ALERTED THE EDITOR HANDLING THE MANUSCRIPT TO THE CHANGE AND THEY SPECIFICALLY HAVE AGREED TO IT.

Please ensure that the paper adheres to the PLOS Data Availability Policy (see <http://journals.plos.org/plosmedicine/s/data-availability>), which requires that all data underlying the study\'s findings be provided in a repository or as Supporting Information. For data residing with a third party, authors are required to provide instructions with contact information for obtaining the data. PLOS journals do not allow statements supported by \"data not shown\" or \"unpublished results.\" For such statements, authors must provide supporting data or cite public sources that include it.

If you have any questions in the meantime, please contact me or the journal staff on <plosmedicine@plos.org>.

We look forward to receiving the revised manuscript by Apr 24 2020 11:59PM.

Sincerely,

Caitlin Moyer, Ph.D.

Associate Editor

PLOS Medicine

[plosmedicine.org](http://plosmedicine.org)

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

Requests from Editors:

1.The Data Availability Statement (DAS) requires revision. For each data source used in your study:

a\) If the data are freely or publicly available, note this and state the location of the data: within the paper, in Supporting Information files, or in a public repository (include the DOI or accession number). Specifically, please provide the direct link for the Phase I genotype data in the database of Genotypes and Phenotypes (dbGaP).

For the remaining (sequencing/array) aggregate data:

Please include an appropriate contact (web or email address) for inquiries (again, this cannot be a study author). When you say "Investigators may contact the Site PIs from Hayes & Urbanek et al. \[18\] if they are interested in collaborating on a project that requires use of quantitative trait data." please note that the present study authors may not serve as the contact points for data access.

2\. Abstract: Methods and Findings: Please include appropriate summary demographic information regarding the individuals included in the analyses.

3\. Abstract: Conclusions: Please revise or remove the final sentence of the abstract to be more congruent with the main findings of the study: "This study demonstrates how precise phenotypic delineation can be more powerful than increases in sample size for genetic association studies." Please mention only specific implications of the study substantiated by the results.

4\. Author Summary: "Why was this study done?": We suggest revising the final bullet point to "Elucidating the genetic mechanisms of PCOS could result in improved diagnosis and treatment." to remove implications of causality.

5 .Author Summary: "What do these findings mean?": Please revise the first bullet point to remove causal language- we suggest: "Our results suggest that there are distinct forms of PCOS that are associated with different underlying biological mechanisms."

6\. Methods: Line 198: Please include the analyses of age and BMI compared between cases included and excluded due to missing quantitative trait data, as PLOS does not permit \"data not shown." (This could be presented in a supporting information file).

7\. Methods: Please provide a summary table to go along with the results of Figure 3 (summary data on quantitative phenotypic trait data).

8\. Figure 1: We request that you please remove this figure from the paper, and re-number the rest of the figures and in-text figure references, accordingly.

9\. Figure 5: In the legend where you refer to "unclassified (grey) clusters" please clarify whether this is the same as the "indeterminate" clusters.

10\. Figure 6: The inset graphs are too small to read easily, please enlarge the fonts for readability. In the legend, please include the panel for "indeterminate" PCOS: "Manhattan plots for (a) reproductive, (b) metabolic, and (c) indeterminate PCOS subtypes."

11\. Figure 7: Please define the abbreviation "OR" in the figure legend.

12\. Figure 8: Please increase the size of the smaller fonts, as they are difficult to read.

13\. Figure 12: Please define abbreviations for PC1/PC2/PCA; DHEAS, LH, FSH, G0, I0, BMI,SHBG in the figure legend. Please explain that the markers indicate affected women and the bold marker outlines represent carriers.

14\. Supporting Information Tables: Please provide titles and legends for each individual table and figure in the Supporting Information.

Comments from Reviewers:

Reviewer \#2: The authors carefully and thoroughly addressed all my concerns. I have no further requests and gladly recommend this manuscript for publication.

Reviewer \#4: My concerns have been met appropriately. So I don\'t have any major or minor concerns regarding this paper.

Any attachments provided with reviews can be seen via the following link:

\[LINK\]

10.1371/journal.pmed.1003132.r004
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13 May 2020

Dear Dr. Dapas,

On behalf of my colleagues and the academic editor, Dr. Jenny Myers, I am delighted to inform you that your manuscript entitled \"Distinct subtypes of polycystic ovary syndrome with novel genetic associations: an unsupervised, phenotypic clustering analysis\" (PMEDICINE-D-19-03066R2) has been accepted for publication in PLOS Medicine.
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